Department of Cardiology, the Xiamen Cardiovascular Hospital of Xiamen University, Xiamen, Fujian, China.
Department of Cardiology, the Xiamen Cardiovascular Hospital of Xiamen University, Xiamen, Fujian, China.
Clin Chim Acta. 2020 Dec;511:40-46. doi: 10.1016/j.cca.2020.09.035. Epub 2020 Sep 28.
Dyslipidaemia is associated with numerous health problems that include the combination of insulin resistance, hypertension and obesity, ie, metabolic syndrome. Although the use of statins to decrease serum low density lipoprotein cholesterol (LDL-C) has been an effective therapeutic in treating atherosclerosis, the persistence of high atherosclerotic risk, ie, residual risk, is notable and is not simply explained as a phenomenon of dyslipidaemia. As such, it is imperative that we identify new biomarkers to monitor treatment and more accurately predict future cardiovascular events. This athero-protective strategy includes the assessment of novel inflammatory biomarkers such as YKL-40. Recent evidence has implicated YKL-40 in patients with inflammatory diseases and cardio-metabolic disorders, making it potentially useful to evaluate disease severity, prognosis and survival. In this review, we summarize role of YKL-40 in the pathogenesis of cardio-metabolic disorders and explore its use as a novel biomarker for monitoring athero-protective therapy.
血脂异常与许多健康问题相关，包括胰岛素抵抗、高血压和肥胖的组合，即代谢综合征。虽然使用他汀类药物降低血清低密度脂蛋白胆固醇（LDL-C）已成为治疗动脉粥样硬化的有效治疗方法，但高动脉粥样硬化风险（即残余风险）仍然存在，这不仅仅是血脂异常现象的简单解释。因此，我们必须确定新的生物标志物来监测治疗效果，并更准确地预测未来的心血管事件。这种动脉保护策略包括评估新型炎症生物标志物，如 YKL-40。最近的证据表明 YKL-40 与炎症性疾病和心脏代谢紊乱有关，因此它可能有助于评估疾病的严重程度、预后和生存率。在这篇综述中，我们总结了 YKL-40 在心脏代谢紊乱发病机制中的作用，并探讨了其作为一种新型生物标志物用于监测动脉保护治疗的用途。
